Translating personalized genomic medicine into clinical practice: Evidence, values, and health policy

Genome

Volumn 58, Issue 12, 2015, Pages 491-497

  Bombard, Yvonne ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; ETHICS; FEMALE; GENETICS; GENOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; MALE; PERSONALIZED MEDICINE; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TRANSLATIONAL RESEARCH;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; GENOME, HUMAN; GENOMICS; HEALTH POLICY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; PRECISION MEDICINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84949562103     PISSN: 08312796     EISSN: None     Source Type: Journal    
DOI: 10.1139/gen-2015-0145     Document Type: Article

References (64)

1. Adair A. Hyde-Lay R. Einsiedel E. Caulfield T. 2009. Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers. BMC Med. Ethics, 10: 6. 19538750.
2. Armstrong K. Weber B. FitzGerald G. Hershey J.C. Pauly M.V. Lemaire J. et al 2003. Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am. J. Med. Genet. 120A: 359-364. 10.1002/ajmg.a.20025. 12838555.
3. Bamshad M.J. Ng S.B. Bigham A.W. Tabor H.K. Emond M.J. Nickerson D.A. Shendure J. 2011. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12: 745-755. 10.1038/nrg3031. 21946919.
4. Bernhardt B.A. Zayac C. Pyeritz R.E. 2011. Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia. Genet. Med. 13: 812-820. 21637104.
5. Bogaerts J. Sydes M.R. Keat N. McConnell A. Benson A. Ho A. et al 2015. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur. J. Cancer, 51: 271-281. 25542058.
6. Bombard Y. Penziner E. Decolongon J. Klimek M.L. Creighton S. Suchowersky O. et al 2007. Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clin. Genet. 71: 220-231. 10.1111/j.1399-0004.2007.00770.x. 17309644.
7. Bombard Y. Veenstra G. Friedman J.M. Creighton S. Currie L. Paulsen J.S. et al 2009. Perceptions of genetic discrimination among people at risk for Huntington?s disease: a cross sectional survey. BMJ, 338: b2175. 10.1136/bmj.b2175. 19509425.
8. Bombard Y. Palin J. Friedman J.M. Veenstra G. Creighton S. Paulsen J.S. et al 2011. Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156 (1): 19-27. 10.1002/ajmg.b.31130.
9. Bombard Y. Palin J. Friedman J.M. Veenstra G. Creighton S. Bottorff J.L. et al 2012. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B: 217-226. 10.1002/ajmg.b.32016. 22231990.
10. Bombard Y. Abelson J. Simeonov D. Gauvin F.P. 2013 a. Citizens? perspectives on personalized medicine: a qualitative public deliberation study. Eur. J. Hum. Genet. 21 (11): 1197-1201. 10.1038/ejhg.2012.300. 23340511.
11. Bombard Y. Bach P.B. Offit K. 2013 b. Translating genomics in cancer care. J. Natl. Compr. Cancer Netw. 11: 1343-1353. 24225968.
12. Bombard Y. Robson M. Offit K. 2013 c. Revealing the incidentalome when targeting the tumor genome. JAMA, 310: 795-796. 10.1001/jama.2013.276573. 23982363.
13. Bombard Y. Rozmovits L. Trudeau M. Leighl N.B. Deal K. Marshall D.A. 2014 a. Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment. Curr. Oncol. 21: e426-e433. 24940102.
14. Bombard Y. Rozmovits L. Trudeau M.E. Leighl N.B. Deal K. Marshall D.A. 2014 b. Patients? perceptions of gene expression profiling in breast cancer treatment decisions. Curr. Oncol. 21: e203-e211. 24764705.
15. Bonter K. Desjardins C. Currier N. Pun J. Ashbury F.D. 2011. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open, 1: e000110. 22021765.
16. Burke W. Psaty B.M. 2007. Personalized medicine in the era of genomics. JAMA, 298: 1682-1684. 10.1001/jama.298.14.1682. 17925520.
17. Canadian Cancer Society. 2014. Cancer statistics at a glance. Vol. 2015.
18. Conti R. Veenstra D.L. Armstrong K. Lesko L.J. Grosse S.D. 2010. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med. Decis. Making, 30: 328-340. 20086232.
19. Evans D.G. Barwell J. Eccles D.M. Collins A. Izatt L. Jacobs C. et al 2014. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 16: 442. 25510853.
20. Canadian Coalition of Genetic Fairness. 2015. Vol. 2015.
21. Geer K.P. Ropka M.E. Cohn W.F. Jones S.M. Miesfeldt S. 2001. Factors influencing patients? decisions to decline cancer genetic counseling services. J. Genet. Counsel. 10: 25-40. 10.1023/A:1009451213035.
22. Government of Canada. 2010. Bill C-56. An act to amend the Canadian Human Rights Act (Genetic Characteristics). In Canadian Charter of Human Rights.
23. Government of Canada. 2012 a. Bill C-44. An Act to Amend the Canadian Human Rights Act (Genetic Characteristics). In Canadian Charter of Human Rights.
24. Government of Canada. 2012 b. Bill S-201. An Act to Prohibit and Prevent Genetic Discrimination. In Canadian Charter of Human Rights.
25. Government of Ontario. 2011. Bill 199. An Act to amend the Human Rights Code with respect to genetic characteristics. In Ontario Human Rights Code.
26. Government of Ontario. 2013. Bill 127. An Act to amend the Human Rights Code with respect to genetic characteristics. In Ontario Human Rights Code.
27. Green R.C. Berg J.S. Grody W.W. Kalia S.S. Nussbaum R.L. O'Daniel J.M. et al 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15: 565-574. 10.1038/gim.2013.73. 23788249.
28. Grosse S.D. Khoury M.J. 2006. What is the clinical utility of genetic testing? Genet. Med. 8: 448-450. 10.1097/01.gim.0000227935.26763.c6. 16845278.
29. Gualandi F. Bigoni S. Melchiorri L. Buldrini B. Balboni A. Neri M. et al 2014. Genetic counseling for women referred for advanced maternal age: a telegenetic approach. Genet. Med. 16: 795. 10.1038/gim.2014.103. 25290261.
30. Hadley D.W. Jenkins J.F. Dimond E. de Carvalho M. Kirsch I. Palmer C.G. 2004. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J. Clin. Oncol. 22: 39-44. 14701766.
31. Hall M.A. Rich S.S. 2000. Patients? fear of genetic discrimination by health insurers: the impact of legal protections. Genet. Med. 2: 214-221. 10.1097/00125817-200007000-00003. 11252705.
32. Hall M.A. McEwen J.E. Barton J.C. Walker A.P. Howe E.G. Reiss J.A. et al 2005. Concerns in a primary care population about genetic discrimination by insurers. Genet. Med. 7: 311-316. 10.1097/01.GIM.0000162874.58370.C0. 15915082.
33. Hamburg M.A. Collins F.S. 2010. The path to personalized medicine. N. Engl. J. Med. 363: 301-304. 10.1056/NEJMp1006304. 20551152.
34. Harris L. Fritsche H. Mennel R. Norton L. Ravdin P. Taube S. et al 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25: 5287-5312. 10.1200/JCO.2007.14.2364. 17954709.
35. Hilgart J.S. Hayward J.A. Coles B. Iredale R. 2012. Telegenetics: a systematic review of telemedicine in genetics services. Genet. Med. 14: 765-776. 10.1038/gim.2012.40.
36. Jarvik G.P. Amendola L.M. Berg J.S. Brothers K. Clayton E.W. Chung W. et al 2014. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am. J. Hum. Genet. 94 (6): 818-826. 10.1016/j.ajhg.2014.04.009. 24814192.
37. Kaye C.I. 2012. Genetic service delivery: infrastructure, assessment and information. Public Health Genomics, 15: 164-171. 10.1159/000335552. 22488459.
38. Kent H. 1999. Waiting list grows for BC?s Hereditary Cancer Program. CMAJ, 161: 1175. 10569112.
39. Keogh L.A. van Vliet C.M. Studdert D.M. Maskiell J.A. Macrae F.A. St John D.J. et al 2009. Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications? Med. J. Aust. 191: 255-258. 19740045.
40. Khoury M.J. Gwinn M. Yoon P.W. Dowling N. Moore C.A. Bradley L. 2007. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet. Med. 9: 665-674. 10.1097/GIM.0b013e31815699d0. 18073579.
41. Lapham E.V. Kozma C. Weiss J.O. 1996. Genetic discrimination: perspectives of consumers. Science, 274: 621-624. 10.1126/science.274.5287.621. 8849455.
42. Li H. Adeli K. 2009. Laboratory quality regulations and accreditation standards in Canada. Clin. Biochem. 42: 249-255. 10.1016/j.clinbiochem.2008.09.006. 19863915.
43. Link D.C. Schuettpelz L.G. Shen D. Wang J. Walter M.J. Kulkarni S. et al 2011. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA, 305: 1568-1576. 10.1001/jama.2011.473. 21505135.
44. Lyman G.H. Cosler L.E. Kuderer N.M. Hornberger J. 2007. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer, 109: 1011-1018. 10.1002/cncr.22506. 17311307.
45. MacLeod R. Tibben A. Frontali M. Evers-Kiebooms G. Jones A. Martinez-Descales A. Roos R.A. 2013. Recommendations for the predictive genetic test in Huntington's disease. Clin. Genet. 83: 221-231. 10.1111/j.1399-0004.2012.01900.x. 22642570.
46. Marchionni L. Wilson R.F. Marinopoulos S.S. Wolff A.C. Parmigiani G. Bass E.B. Goodman S.N. 2007. Impact of gene expression profiling tests on breast cancer outcomes. Evid. Rep. Technol. Assess. 160: 1-105. 18457476.
47. Marteau, T.M., French, D.P., Griffin, S.J., Prevost, A.T., Sutton, S., Watkinson, C., et al. 2010. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst. Rev. 2010, Iss. 10. Art. No. CD007275. 10.1002/14651858.CD007275.pub2.
48. Miller F.A. Krueger P. Christensen R.J. Ahern C. Carter R.F. Kamel-Reid S. 2009. Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Services Res. 9: 131. 10.1186/1472-6963-9-131.
49. Ormond K.E. Wheeler M.T. Hudgins L. Klein T.E. Butte A.J. Altman R.B. et al 2010. Challenges in the clinical application of whole-genome sequencing. Lancet, 375: 1749-1751. 10.1016/S0140-6736(10)60599-5. 20434765.
50. Otlowski M. Taylor S. Bombard Y. 2012. Genetic discrimination: international perspectives. Annu. Rev. Genomics Hum. Genet. 13: 433-454. 10.1146/annurev-genom-090711-163800. 22607273.
51. Otten, E., Birnie, E., Lucassen, A.M., Ranchor, A.V., and Van Langen, I.M. 2015. Telemedicine uptake among Genetics Professionals in Europe: room for expansion. Eur. J. Hum. Genet. 10.1038/ejhg.2015.83.
52. Paik S. Shak S. Tang G. Kim C. Baker J. Cronin M. et al 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351: 2817-2826. 10.1056/NEJMoa041588. 15591335.
53. Paik S. Tang G. Shak S. Kim C. Baker J. Kim W. et al 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24: 3726-3734. 10.1200/JCO.2005.04.7985. 16720680.
54. Pasche B. Absher D. 2011. Whole-genome sequencing: a step closer to personalized medicine. JAMA, 305: 1596-1597. 10.1001/jama.2011.484. 21505140.
55. Persing M. Grosse R. 2007. Current St. Gallen recommendations on primary therapy of early breast cancer. Breast Care, 2: 137-140. 10.1159/000103752.
56. Sanderson S.C. 2013. Genome sequencing for healthy individuals. Trends Genet. 29: 556-558. 10.1016/j.tig.2013.08.005. 24035073.
57. Schrijver I. Aziz N. Farkas D.H. Furtado M. Gonzalez A.F. Greiner T.C. et al 2012. Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the association for molecular pathology. J. Mol. Diagn. 14: 525-540. 10.1016/j.jmoldx.2012.04.006. 22918138.
58. Schunemann H.J. Oxman A.D. Brozek J. Glasziou P. Jaeschke R. Vist G.E. et al 2008. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (Clinical research ed.), 336: 1106-1110. 10.1136/bmj.39500.677199.AE.
59. Thompson H.S. Valdimarsdottir H.B. Duteau-Buck C. Guevarra J. Bovbjerg D.H. Richmond-Avellaneda C. et al 2002. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol. Biomarkers Prev. 11: 1579-1585. 12496047.
60. Tsoi D.T. Inoue M. Kelly C.M. Verma S. Pritchard K.I. 2010. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist, 15: 457-465. 10.1634/theoncologist.2009-0275. 20421264.
61. Walker, P. 2013. DNA of 100,000 people to be mapped for NHS. In The Guardian, London.
62. Welch J.S. Westervelt P. Ding L. Larson D.E. Klco J.M. Kulkarni S. et al 2011. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA, 305: 1577-1584. 10.1001/jama.2011.497. 21505136.
63. Wideroff L. Phillips K.A. Randhawa G. Ambs A. Armstrong K. Bennett C.L. et al 2009. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics, 12: 233-244. 10.1159/000203779. 19367091.
64. Xue Y. Chen Y. Ayub Q. Huang N. Ball E.V. Mort M. et al 2012. Deleterious-and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am. J. Hum. Genet. 91: 1022-1032. 10.1016/j.ajhg.2012.10.015. 23217326.